Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13031333 | 0.83 | GFER (0.40) | GFERRAB9AMEN1ALDH1A1KMT2A | |
| SCHEMBL11736157 | 0.81 | GFER (0.56) | GFERRAB9AMEN1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL3586167 | 0.80 | GFER (0.55) | GFERRAB9AMEN1ALDH1A1KMT2A | |
| SCHEMBL2960305 | 0.78 | ALPL (0.50) | GFERMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL13010096 | 0.77 | TLR8 (0.45) | ALDH1A1KMT2ASMN1; SMN2LMNAPOLB | |
| SCHEMBL13072246 | 0.76 | SMN1; SMN2 (0.39) | GFERMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3582565 | 0.75 | FPR2 (0.43) | ALDH1A1KMT2ASMN1; SMN2GAA | |
| SCHEMBL4963238 | 0.74 | SMN1; SMN2 (0.40) | MEN1ALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL5765600 | 0.73 | SMN1; SMN2 (0.42) | GFERALDH1A1KMT2ASMN1; SMN2POLB | |
| SCHEMBL3596407 | 0.73 | GAA (0.38) | RAB9AALDH1A1SMN1; SMN2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | GFER 2861/4885RAB9A 2780/4885MEN1 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.